Posts by: Alice Melão

News

Five Prime Therapeutics’ ongoing Phase 1 clinical trial has advanced to its Phase 1b expansion portion, in which researchers have begun giving breast, ovarian, and endometrial cancer patients an optimal dose ... Read more

March 4, 2019

Phase 2 Trial Completes Dosing First OC Patient with Aivita’s Cell Therapy

News

A Phase 2 trial exploring Aivita Biomedical’s cell therapy AVOVA-1 for ovarian cancer has treated its first patient and continues to recruit participants across eight sites in the United States. So far, ... Read more

March 1, 2019

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

News

A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 trial ... Read more

February 15, 2019

1st Patient Dosed in Phase 1/2 Trial of COTI-2 Plus Chemo for Gynecological and Other Solid Cancers

News

A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga Pharmaceuticals, ... Read more

January 4, 2019

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

News

Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line ... Read more

November 12, 2018

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

News

Cristal Therapeutics has begun patient dosing in its Phase 2a trial evaluating CPC634 — the chemotherapy docetaxel, delivered in nanoparticles — in patients whose ovarian cancer has become resistant to platinum-based ... Read more

October 26, 2018

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

News

The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody that targets ... Read more

September 19, 2018

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

News

IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is expected ... Read more

August 10, 2018

Collaboration Tests TRX518-Bavencio Combo in Phase 1/2 Trial of Solid Tumors

News

Leap Therapeutics is launching a Phase 1/2 clinical trial to test its immunotherapy TRX518 in combination with Bavencio (avelumab) and chemotherapy in advanced solid tumors, as part of a collaboration established with Merck KGaA and Pfizer — the two ... Read more

July 20, 2018

Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers

News

A new Phase 1/2 clinical trial has been launched testing a combination of investigational viral therapy ONCOS-102 and Imfinzi (durvalumab) in patients with advanced ovarian and colorectal cancers. The open-label trial ... Read more